Literature DB >> 11473030

Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor.

R Burcelin1, A Da Costa, D Drucker, B Thorens.   

Abstract

Activation of the hepatoportal glucose sensors by portal glucose infusion leads to increased glucose clearance and induction of hypoglycemia. Here, we investigated whether glucagon-like peptide-1 (GLP-1) could modulate the activity of these sensors. Mice were therefore infused with saline (S-mice) or glucose (P-mice) through the portal vein at a rate of 25 mg/kg. min. In P-mice, glucose clearance increased to 67.5 +/- 3.7 mg/kg. min as compared with 24.1 +/- 1.5 mg/kg. min in S-mice, and glycemia decreased from 5.0 +/- 0.1 to 3.3 +/- 0.1 mmol/l at the end of the 3-h infusion period. Coinfusion of GLP-1 with glucose into the portal vein at a rate of 5 pmol/kg. min (P-GLP-1 mice) did not increase the glucose clearance rate (57.4 +/- 5.0 ml/kg. min) and hypoglycemia (3.8 +/- 0.1 mmol/l) observed in P-mice. In contrast, coinfusion of glucose and the GLP-1 receptor antagonist exendin-(9-39) into the portal vein at a rate of 0.5 pmol/kg. min (P-Ex mice) reduced glucose clearance to 36.1 +/- 2.6 ml/kg. min and transiently increased glycemia to 9.2 +/- 0.3 mmol/l at 60 min of infusion before it returned to the fasting level (5.6 +/- 0.3 mmol/l) at 3 h. When glucose and exendin-(9-39) were infused through the portal and femoral veins, respectively, glucose clearance increased to 70.0 +/- 4.6 ml/kg. min and glycemia decreased to 3.1 +/- 0.1 mmol/l, indicating that exendin-(9-39) has an effect only when infused into the portal vein. Finally, portal vein infusion of glucose in GLP-1 receptor(-/-) mice failed to increase the glucose clearance rate (26.7 +/- 2.9 ml/kg. min). Glycemia increased to 8.5 +/- 0.5 mmol/l at 60 min and remained elevated until the end of the glucose infusion (8.2 +/- 0.4 mmol/l). Together, our data show that the GLP-1 receptor is part of the hepatoportal glucose sensor and that basal fasting levels of GLP-1 sufficiently activate the receptor to confer maximum glucose competence to the sensor. These data demonstrate an important extrapancreatic effect of GLP-1 in the control of glucose homeostasis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11473030     DOI: 10.2337/diabetes.50.8.1720

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  66 in total

1.  GLUT4, AMP kinase, but not the insulin receptor, are required for hepatoportal glucose sensor-stimulated muscle glucose utilization.

Authors:  Rémy Burcelin; Valerie Crivelli; Christophe Perrin; Anabela Da Costa; James Mu; Barbara B Kahn; Morris J Birnbaum; C Ronald Kahn; Peter Vollenweider; Bernard Thorens
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

2.  Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors.

Authors:  Frédéric Preitner; Mark Ibberson; Isobel Franklin; Christophe Binnert; Mario Pende; Asllan Gjinovci; Tanya Hansotia; Daniel J Drucker; Claes Wollheim; Rémy Burcelin; Bernard Thorens
Journal:  J Clin Invest       Date:  2004-02       Impact factor: 14.808

3.  The role of sodium-coupled glucose co-transporter 3 in the satiety effect of portal glucose sensing.

Authors:  Fabien Delaere; Adeline Duchampt; Lourdes Mounien; Pascal Seyer; Céline Duraffourd; Carine Zitoun; Bernard Thorens; Gilles Mithieux
Journal:  Mol Metab       Date:  2012-12-07       Impact factor: 7.422

4.  Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors.

Authors:  J J Holst; C F Deacon
Journal:  Diabetologia       Date:  2005-03-10       Impact factor: 10.122

Review 5.  Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

Authors:  M A Nauck; I Vardarli; C F Deacon; J J Holst; J J Meier
Journal:  Diabetologia       Date:  2010-09-25       Impact factor: 10.122

6.  Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage.

Authors:  Claude Knauf; Patrice D Cani; Christophe Perrin; Miguel A Iglesias; Jean François Maury; Elodie Bernard; Fadilha Benhamed; Thierry Grémeaux; Daniel J Drucker; C Ronald Kahn; Jean Girard; Jean François Tanti; Nathalie M Delzenne; Catherine Postic; Rémy Burcelin
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

Review 7.  Is Glucagon-like peptide-1, an agent treating diabetes, a new hope for Alzheimer's disease?

Authors:  Lin Li
Journal:  Neurosci Bull       Date:  2007-01       Impact factor: 5.203

Review 8.  The role of incretins in glucose homeostasis and diabetes treatment.

Authors:  Wook Kim; Josephine M Egan
Journal:  Pharmacol Rev       Date:  2008-12-12       Impact factor: 25.468

9.  Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.

Authors:  David A D'Alessio; Amanda M Denney; Linda M Hermiller; Ronald L Prigeon; Julie M Martin; William G Tharp; Monica Liqueros Saylan; Yanling He; Beth E Dunning; James E Foley; Richard E Pratley
Journal:  J Clin Endocrinol Metab       Date:  2008-10-28       Impact factor: 5.958

10.  Colesevelam suppresses hepatic glycogenolysis by TGR5-mediated induction of GLP-1 action in DIO mice.

Authors:  Matthew J Potthoff; Austin Potts; Tianteng He; João A G Duarte; Ronald Taussig; David J Mangelsdorf; Steven A Kliewer; Shawn C Burgess
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-12-20       Impact factor: 4.052

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.